Ørskov Andreas Due, Grønbæk Kirsten
From the Department of Haematology, Rigshospitalet, Copenhagen University Hospital, and Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
Cancer J. 2017 Sep/Oct;23(5):277-285. doi: 10.1097/PPO.0000000000000282.
DNA methyltransferase inhibitors, so-called hypomethylating agents (HMAs), are the only drugs approved for the treatment of higher-risk myelodysplastic syndromes and are widely used in this context. However, it is still unclear why some patients respond to HMAs, whereas others do not. Recent sequencing efforts have identified molecular disease entities that may be specifically sensitive to these drugs, and many attempts are being made to clarify how HMAs affect the malignant clone during treatment. Here, we review the most recent data on the clinical effects of HMAs in myeloid malignancies.
DNA甲基转移酶抑制剂，即所谓的低甲基化剂（HMAs），是唯一被批准用于治疗高危骨髓增生异常综合征的药物，并在这一领域广泛应用。然而，仍不清楚为何有些患者对HMAs有反应，而其他患者则没有。最近的测序工作已鉴定出可能对这些药物特别敏感的分子疾病实体，并且正在进行许多尝试以阐明HMAs在治疗过程中如何影响恶性克隆。在此，我们综述了关于HMAs在髓系恶性肿瘤中临床效应的最新数据。
